



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Scientific Letter

Forecasting COVID-19 Infection Trends and New Hospital Admissions in Spain due to SARS-CoV-2 Variant of Concern Omicron



Estimación de las tendencias de infección por COVID-19 y de nuevos ingresos hospitalarios en España debido a la variante Ómicron del SARS-CoV-2

To the Director:

Spain has been among the hardest hit countries by COVID-19 worldwide, particularly during the first wave and the ongoing sixth wave.¹ There have been several successful attempts to forecast trends of incidence and mortality of COVID-19, most based upon knowledge on viral dynamics from previous pandemics, recent COVID-19 geographical information of diverse granularity, and newly discovered viral characteristics.^{2–4} However, SARS-CoV-2 inherent poor quality RNA_m copy-editing gene replication makes it prone to mutate and spontaneously create new variants of concern (VoC) (Fig. 1),⁵ that adapt to any hostile environment, produce new outbreaks, and modify existing epidemiological projections.⁶

On November 26, 2021, WHO designated the variant B.1.1.529 as a new VoC, named Omicron, originally identified in South Africa,⁷ on the evidence that mutations in Omicron may have an impact on how it spreads, resistance to vaccination, or the severity of illness it causes.⁸ In particular, in South Africa up to December 2, 2021 it was

observed a doubling time for the first 3 days after the wave threshold of ten cases per 100 000 population.^{9,10} In Denmark, a European leader in sequencing SARS-CoV-2 VoC, where testing of all positive PCR tests is commonplace, cases of Omicron were reported to double every second day,¹¹ despite almost 75% of those infected by Omicron had received full (two doses of) COVID-19 vaccination already.

We used our previous modelling algorithms,^{12–14} to forecast the spread of Omicron in Spain, and report trends in daily cases with a 7-day moving average and of new hospitalisations. We followed EQUATOR's TRIPOD guidance for multivariable prediction models.¹⁵ By applying firstly a third-degree polynomial curve in existing epidemiological trends on the spread of Omicron in Spain, starting from the first 17 days of the Omicron outbreak (from December 12, 2021), and secondly a Gaussian curve following a parametric growth,^{12–14} we were able to model new infections of COVID-19 in Spain. Overall, the worse scenario is forecasting up to 431,348 COVID-19 daily infections on January, 24, 2022 while the “best” scenario is 247,620 (Fig. 2).

Then we modelled these trends for new COVID-19 cases and hospital admissions using a new Gaussian curve to estimate a downward trend after a peak,¹⁶ and we obtained the expected curve of new COVID-19 infections in Spain, and with a 5-day lag time, new hospital admissions. It will likely produce crowding in hospitals, as new hospital admissions per day might peak on January 30, 2022, with a range in between 4210 (“best” scenario) and




Fig. 1. Genomic epidemiology of novel coronavirus – global subsampling.

Footnote: Note in red colour the recent surge of VOC Omicron.




Fig. 2. Trends in COVID-19 daily new infections with a seven-day moving average and of new hospital admissions in Spain, observed and expected up to February 15, 2022.

7333 (worse scenario). Both epidemiological indicators will surpass previous rates observed in the previous five waves, unless both individual and group interventions are taking place. Beyond the futility of debating on an alleged lower severity of Omicron's acute COVID-19 clinical expression, any further consequences on its sequelae and long COVID will require close monitoring.¹⁷

In probability theory, the conditional expectation of any warning system for an eventual surge of an infectious outbreak, as could happen with Omicron substituting other SAR-CoV-2 VoC, modifies (reduces) the eventual magnitude of the event itself.¹⁸ Given preliminary evidence from South Africa, our forecast anticipates a large COVID-19 increase in Spain despite the high levels of vaccination.¹⁹ Therefore, this warning is calling for further reinforcing of universal hygiene interventions (indoor ventilation, social distance, and face masks), and anticipating the need of new lockdowns,¹¹ the latter being extremely detrimental to the economy.

All viruses change in time and space by natural or artificial Darwin's selection, and survival of the fittest,²⁰ due either to high levels of herd immunity or low vaccination coverage. The toll associated with Omicron underlines WHO's COVID-19 message that "No one will be safe, until the entire World is safe (ergo vaccinated)".

Funding

None declared.

References

- World Health Organization. WHO Coronavirus (COVID-19) Dashboard; 2021. <https://covid19.who.int> [last accessed 30.12.21].
- Giordano G, Blanchini F, Bruno R, Colaneri P, Di Filippo A, Di Matteo A, et al. Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy. *Nat Med*. 2020;26:855–60. <http://dx.doi.org/10.1038/s41591-020-0883-7>. Epub 2020 Apr 22. PMID: 32322102.
- Nadella P, Swaminathan A, Subramanian SV. Forecasting efforts from prior epidemics and COVID-19 predictions. *Eur J Epidemiol*. 2020;35:727–9. <http://dx.doi.org/10.1007/s10654-020-00661-0>. Epub 2020 Jul 17. PMID: 32676971.
- Santiago Pérez MI, López-Vizcaíno E, Ruano-Ravina A, Pérez-Ríos M. [A proposed epidemiologic risk threshold for SARS-CoV-2 for assisting health-care decision-making]. *Arch Bronconeumol*. 2021;57:21–7. <http://dx.doi.org/10.1016/j.arbres.2020.12.036>. Epub 2021 Jan 23. PMID: 34629639.
- Nextstrain. Genomic epidemiology of novel coronavirus – global subsampling; 2021. <https://nextstrain.org/ncov/gisaid/global> [last accessed 30.12.21].
- García-Basteiro AL, Chaccour C, Guinovart C, Llupià A, Brew J, Trilla A, et al. Monitoring the COVID-19 epidemic in the context of widespread local transmission. *Lancet Respir Med*. 2020;8:440–2. [http://dx.doi.org/10.1016/S2213-2600\(20\)30162-4](http://dx.doi.org/10.1016/S2213-2600(20)30162-4). Epub 2020 Apr 2. PMID: 32247325.
- Update on Omicron. WHO; 2021. <https://www.who.int/news/item/28-11-2021-update-on-omicron> [last accessed 27.12.21].
- Callaway E, Ledford H. How bad is Omicron? What scientists know so far. *Nature*. 2021;600:197–9. <http://dx.doi.org/10.1038/d41586-021-03614-z>. PMID: 34857948.
- Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. *Lancet*. 2021. [http://dx.doi.org/10.1016/S0140-6736\(21\)02758-6](http://dx.doi.org/10.1016/S0140-6736(21)02758-6). S0140-6736(21)02758-6. Online ahead of print. PMID: 34871545.
- Department of Health, Government of South Africa. COVID-19; 2021. <https://sacoronavirus.co.za/> [accessed 02.12.21].
- Rolander N. Denmark's Omicron surge is a warning to the rest of world. *Bloomberg*; 2021. <https://www.bloomberg.com/news/articles/2021-12-10-denmark-s-omicron-surge-is-a-warning-to-the-rest-of-world> [last accessed 13.12.21].
- Gerli AG, Centanni S, Miozzo MR, Virchow JC, Sotgiu G, Canonica GW, et al. COVID-19 mortality rates in the European Union Switzerland, and the UK: effect of timeliness, lockdown rigidity, and population density. *Minerva Med*. 2020;111:308–14. <http://dx.doi.org/10.23736/S0026-4806.20.06702-6>. Epub 2020 Jun 2. PMID: 32491297.
- Gerli AG, Centanni S, Miozzo M, Sotgiu G. Predictive models for COVID-19-related deaths and infections. *Int J Tuberc Lung Dis*. 2020;24:647–50. <http://dx.doi.org/10.5588/ijtld.20.0196>. PMID: 32552999.
- Gerli AG, Centanni S, Soriano JB, Ancochea J. Forecasting COVID-19 infection trends in the EU-27 countries, the UK and Switzerland due to SARS-CoV-2 variant of concern Omicron. *medRxiv*. 2021. <https://medrxiv.org/cgi/content/short/2021.12.16.21267785v1> [preprint].
- Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. <https://www.equator-network.org/reporting-guidelines/tripod-statement/> [accessed 14.12.21].
- Dhamodharavadhani S, Rathipriya R. COVID-19 mortality rate prediction for India using statistical neural networks and Gaussian process regression model. *Afr Health Sci*. 2021;21:194–206. <http://dx.doi.org/10.4314/ahs.v21i1.26>. PMID: 34394298.
- Menéndez R, Ceccato A, Martín-Loeches I, Motos A, Barbé F, Peces-Barba G, et al. [Evaluation of respiratory sequelae in patients with COVID-19, where we are and where we are going. CIBERESUCICOVID and RECOVID studies to compare patients admitted to ICU vs conventional ward]. *Arch Bronconeumol*. 2021. <http://dx.doi.org/10.1016/j.arbres.2021.09.013>. Oct 5. Online ahead of print. PMID: 34629615.
- Billingsley P. Section 34. Conditional expectation. In: *Probability and measure*. 3rd ed. John Wiley & Sons; 1995. ISBN 0-471-00710-2. p. 445.
- Rae M. Omicron: a failure to act with a global focus will continue the proliferation of new variants of COVID-19. *BMJ*. 2021;375:n3095. <http://dx.doi.org/10.1136/bmj.n3095>. PMID: 34916212.
- Wang R, Chen J, Wei GW. Mechanisms of SARS-CoV-2 evolution revealing vaccine-resistant mutations in Europe and America. *J Phys Chem Lett*. 2021;7:11850–7. <http://dx.doi.org/10.1021/acs.jpclett.1c03380>. Online ahead of print. PMID: 34873910.

Joan B. Soriano^{a,b,c,*}, Alberto Giovanni Gerli^d, Stefano Centanni^{e,f},
Julio Ancochea^{a,b,c}

^a Servicio de Neumología, Hospital Universitario La Princesa, Madrid, Spain

^b Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain

^c Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Madrid, Spain

^d Department of Health Sciences, Università degli Studi di Milano, Milan, Italy

^e Respiratory Unit, ASST Santi Paolo e Carlo, Milan, Italy

^f Department of Health Sciences, Università degli Studi di Milano, Milan, Italy

Corresponding author.

E-mail address: jbsoriano2@gmail.com (J.B. Soriano).